Email
Password
Remember meForgot password?
    Log in with Twitter

article imageTwo new antibiotics developed

By Tim Sandle     Jun 8, 2014 in Science
Reversing the long period where no new antibiotics have been developed, two new drugs could be available within a matter of months.
The first of the new antibiotics is called Dalvance. This is an intravenous drug that can treat skin and soft tissue infections. Dalvance was approved by the U.S. Food and Drug Administration (FDA) towards the end of May 2014. Dalvance is intended to treat acute bacterial skin and skin structure infections caused by certain susceptible bacteria like Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains, that is, MRSA).
To evaluate the safety and efficacy of Dalvance, the antibiotic was evaluated in two clinical trials using a total of 1,289 adults with acute bacterial skin and skin structure infections. Participants were randomly assigned to receive Dalvance or the alternative antibiotic vancomycin. Results showed Dalvance was as effective as vancomycin for the treatment of the bacterial skin diseases. Given the growing resistance of different bacteria, notably S. aureus, to vancomycin, this development represents a significant step forwards. This was the the first drug to be approved via FDA’s new Generating Antibiotic Incentives Now program,
The second drug is called Oritavancin. This was the subject of a clinical trial study led by G. Ralph Corey of Duke University, and the success was announced in the June 2014 edition of the journal The New England Journal of Medicine (the paper is titled "Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections"). This drug works in a similar way and is also administered by infusion.
Commenting on the news about the two new medicines, Vanderbilt University’s William Schaffner, an infectious disease specialist who was independent of the two studies, told the New York Times: "This is a bit of a light at the end of a dismal tunnel in the development of new antibiotics."
Given that antibiotic resistance is a major threat to human health worldwide, these developments are to be welcomed. However, they are but two new medical advancements at a time when dozens more are required.
More about Antibiotics, MRSA, Bacteria, Infection, Skin
More news from
Latest News
Top News